Gerhard Koenig

Gerhard Koenig is a prominent figure in the field of neurobiology and biotechnology, currently serving as Founder, President, and CEO of Arkuda Therapeutics since February 2018, where the focus is on addressing neurodegenerative diseases. In addition to this role, Gerhard serves on the board of Vigil Therapeutics and is the Non-Executive Chairman of Augustine Therapeutics, further emphasizing a commitment to innovative solutions in neuroscience. Previous experience includes leadership positions such as President and CEO of Quartet Medicine, Chief Scientific Officer and Senior Vice President of Research at FORUM Pharmaceuticals, and Director of the Neurodegeneration Department at Bayer. Gerhard’s academic background includes a Ph.D. in Neuroscience from Heidelberg University, enhancing expertise in research and development within the biotechnology landscape.